{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-060816","form_type":"8-K","ticker":null,"cik":"0001760173","company_name":"SURGALIGN HOLDINGS, INC.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.443391+00:00","generated_at":"2026-06-18T11:56:31.119242+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Surgalign sells Coflex/Cofix product lines to Xtant Medical for $17M cash","bullets":["Sold 100% of Surgalign SPV equity to Xtant Medical for $17M cash.","Transaction closed Feb 28, 2023; includes Coflex/Cofix product lines and worldwide IP.","Pro forma shows removal of ~$10.9M revenue (9M 2022) and ~$17.8M (FY2021).","Estimated gain on disposal of $13.5M recorded in pro forma; actual gain in Q1 2023.","Transition services agreement signed for post-closing support."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-060816","json":"https://secwatch.observer/filing/0001193125-23-060816.json","markdown":"https://secwatch.observer/filing/0001193125-23-060816.md","text":"https://secwatch.observer/filing/0001193125-23-060816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760173/000119312523060816/0001193125-23-060816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760173/000119312523060816/d439544d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:56:31.119242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ee9d3ca7c6e5f34bdfcfa1653624e656c6101aeb","claim":"SURGALIGN HOLDINGS, INC. completed a disposition involving Xtant Medical Holdings, Inc. for $17.0 million in cash (closed 2023-02-28).","evidence_excerpt":"the aggregate consideration paid in the Coflex Transaction for 100% of Surgalign SPV's equity securities was $17.0 million in cash","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760173/000119312523060816/0001193125-23-060816-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Xtant Medical Holdings, Inc."},{"label":"Consideration","value":"$17.0 million in cash"},{"label":"Closing","value":"2023-02-28"}],"fact_type":"ma_transaction"},{"claim_id":"2f39c8b00894aceaf6cdd2452fd1a65a2ecb82eb","claim":"SURGALIGN HOLDINGS, INC. entered into Transition Services Agreement with Xtant Medical Holdings, Inc. (effective 2023-02-28).","evidence_excerpt":"Seller, Surgalign SPV and Xtant also entered into a Transition Services Agreement, dated as of February 28, 2023 (the “Transition Services Agreement”), in connection with the Coflex Transaction pursuant to which Seller has agreed to provide certain transition services to Xtant immediately after the closing for an agreed upon transition period.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760173/000119312523060816/0001193125-23-060816-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Xtant Medical Holdings, Inc."},{"label":"Effective","value":"2023-02-28"}],"fact_type":"material_agreement"},{"claim_id":"c6280d15d005ead898ebea94a1e2d50bed9580e0","claim":"SURGALIGN HOLDINGS, INC. entered into Equity Purchase Agreement with Xtant Medical Holdings, Inc. valued at $17.0 million (effective 2023-02-28).","evidence_excerpt":"., a Delaware corporation (“Surgalign SPV”) an indirect subsidiary of Surgalign Holdings, Inc., a Delaware corporation (the “Company”), Surgalign Spine Technologies, Inc, a Delaware corporation and sole stockholder of Surgalign SPV (“Seller”), the Company and Xtant Medical Holdings, Inc., a Delaware corporation (“Xtant” or “Buyer”) entered into an Equity Purchase Agreement (the “Coflex Purchase Agreement”), pursuant to which, among other things and concurrently with execution thereof, Xtant acquired 100% of the issued and outstanding equity of Surgalign SPV, from Seller (the “Coflex Transaction”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760173/000119312523060816/0001193125-23-060816-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Xtant Medical Holdings, Inc."},{"label":"Value","value":"$17.0 million"},{"label":"Effective","value":"2023-02-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}